首页> 美国卫生研究院文献>Frontiers in Oncology >The Effect of Post-mastectomy Radiotherapy in Patients With Metaplastic Breast Cancer: An Analysis of SEER Database
【2h】

The Effect of Post-mastectomy Radiotherapy in Patients With Metaplastic Breast Cancer: An Analysis of SEER Database

机译:乳房切除术后放疗对增生性乳腺癌患者的影响:SEER数据库分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Introduction: Metaplastic breast cancer (MBC) is a rare and aggressive form of breast cancer. The present study aimed to assess the effect of post-mastectomy radiotherapy (PMRT) in MBC patients with intermediate-risk (T1-2N1M0 and T3N0M0) and high-risk (T1-4N2-3M0 and T4N0-1M0) disease.Methods: The Surveillance, Epidemiology and End Results database was used to analyze patients with MBC between 2000 and 2014. Kaplan–Meier analysis, log-rank tests, and the multivariate Cox proportional model were used for statistical analysis.Results: We identified 460 patients with a median follow-up time of 31 months (range, 2–178 months). Five-year breast cancer specific survival (BCSS) for all patients was 57.5%. In the entire group, multivariate analysis showed that PMRT was associated with better BCSS (hazard ratio (HR) 0.500, 95% confidence interval (CI) 0.366–0.683, P < 0.001). The 5-year BCSS in PMRT and non-PMRT groups were 62.3 and 50.3%, respectively (P = 0.001). When stratified the patients into intermediate-risk and high-risk groups, PMRT could improve BCSS compared with that in non-PMRT patients in both the intermediate- and high-risk groups. For the intermediate-risk group, the 5-year BCSS was 74.3 and 64.7% in PMRT and non-PMRT groups (P = 0.042), respectively, and was 52.1 and 28.8% in high-risk patients treated with PMRT and non-PMRT, respectively (P < 0.001).Conclusion: PMRT could improve the BCSS of MBC patients with intermediate- and high-risk disease.
机译:简介:化生性乳腺癌(MBC)是一种罕见的侵袭性乳腺癌。本研究旨在评估乳房切除术后放疗(PMRT)对中度风险(T1-2N1M0和T3N0M0)和高风险(T1-4N2-3M0和T4N0-1M0)的MBC患者的疗效。方法:使用监测,流行病学和最终结果数据库分析2000年至2014年之间的MBC患者。使用Kaplan–Meier分析,对数秩检验和多元Cox比例模型进行统计分析。 >结果:我们确定了460例患者,中位随访时间为31个月(范围2–178个月)。所有患者的五年乳腺癌特异性生存率(BCSS)为57.5%。在整个组中,多变量分析显示PMRT与更好的BCSS相关(危险比(HR)0.500,95%置信区间(CI)0.366–0.683,P <0.001)。 PMRT和非PMRT组的5年BCSS分别为62.3%和50.3%(P = 0.001)。当将患者分为中危和高危组时,相比中危和高危组的非PMRT患者,PMRT可以改善BCSS。对于中危组,PMRT组和非PMRT组的5年BCSS分别为74.3和64.7%(P = 0.042),在接受PMRT和非PMRT治疗的高危患者中,其5年BCSS分别为52.1和28.8% ,分别为(P <0.001)。结论: PMRT可以改善中度和高危疾病MBC患者的BCSS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号